The story of Viagra and its creator , copyright, presents a complex picture for prospective investors. While the blockbuster drug initially produced enormous profits , its exclusivity has lapsed , leading to competing alternatives flooding the arena. This reduction in value presents a significant challenge for copyright and any portfolio considerin